Assignee
INCYTE CORP
US·593 granted patents·363 pending applications·8,575 citations·filing 1995–2025
Top patents by PatentIndex Score
956 records- 0199US11566026B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2020·Granted Jan 31, 2023·16 cites·19 claims
- 0299US11331320B2Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitorsINCYTE CORP·Filed 2020·Granted May 17, 2022·12 cites·21 claims
- 0399US11285140B2Piperidin-4-yl azetidine derivatives as JAK1 inhibitorsINCYTE CORP·Filed 2020·Granted Mar 29, 2022·14 cites·2 claims
- 0499US11059821B21H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteinsINCYTE CORP·Filed 2020·Granted Jul 13, 2021·13 cites·26 claims
- 0599US10639310B2Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitorsINCYTE CORP·Filed 2018·Granted May 5, 2020·20 cites·6 claims
- 0699US10398699B2Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitorsINCYTE CORP·Filed 2018·Granted Sep 3, 2019·31 cites·7 claims
- 0799US9974790B2Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitorsINCYTE CORP·Filed 2016·Granted May 22, 2018·40 cites·14 claims
- 0899US9938294B2Tricyclic heterocycles as BET protein inhibitorsINCYTE CORP·Filed 2017·Granted Apr 10, 2018·24 cites·14 claims
- 0999US9624241B2Tricyclic heterocycles as BET protein inhibitorsINCYTE CORP·Filed 2015·Granted Apr 18, 2017·27 cites·8 claims
- 1099US9623029B23-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]octane- or heptane-nitrile as JAK inhibitorsINCYTE CORP·Filed 2015·Granted Apr 18, 2017·44 cites·11 claims
- 1199US9181271B2Tricyclic fused thiophene derivatives as JAK inhibitorsINCYTE CORP·Filed 2013·Granted Nov 10, 2015·105 cites·6 claims
- 1299US9079912B2Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitorsINCYTE CORP·Filed 2014·Granted Jul 14, 2015·75 cites·6 claims
- 1399US8829013B1Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrileINCYTE CORP·Filed 2014·Granted Sep 9, 2014·91 cites·14 claims
- 1499US8822481B1Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrileINCYTE CORP·Filed 2014·Granted Sep 2, 2014·89 cites·28 claims
- 1599US8722693B2Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrileINCYTE CORP·Filed 2013·Granted May 13, 2014·143 cites·10 claims
- 1699US8053433B2Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-5-yl-amines as janus kinase inhibitorsINCYTE CORP·Filed 2007·Granted Nov 8, 2011·107 cites·15 claims
- 1799US7767675B2Imidazotriazines and imidazopyrimidines as kinase inhibitorsINCYTE CORP·Filed 2007·Granted Aug 3, 2010·85 cites·85 claims
- 1899US7598257B2Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitorsINCYTE CORP·Filed 2006·Granted Oct 6, 2009·328 cites·8 claims
- 1999US7335667B2Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-4-yl-amines as Janus kinase inhibitorsINCYTE CORP·Filed 2005·Granted Feb 26, 2008·149 cites·38 claims
- 2099US6645499B1Human ena/VASP-like protein splice variantINCYTE CORP·Filed 1999·Granted Nov 11, 2003·211 cites·2 claims
- 2198US12084443B2Process of preparing a PD-1/PD-L1 inhibitorINCYTE CORP·Filed 2023·Granted Sep 10, 2024·5 cites·9 claims
- 2298US11866435B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2022·Granted Jan 9, 2024·7 cites·21 claims
- 2398US11787793B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2022·Granted Oct 17, 2023·9 cites·25 claims
- 2498US11760756B2Crystalline form of a PD-1/PD-L1 inhibitorINCYTE CORP·Filed 2021·Granted Sep 19, 2023·9 cites·46 claims
- 2598US11753406B2Salts of a PD-1/PD-L1 inhibitorINCYTE CORP·Filed 2020·Granted Sep 12, 2023·9 cites·23 claims
- 2698US11718605B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2020·Granted Aug 8, 2023·11 cites·28 claims
- 2798US11673883B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2020·Granted Jun 13, 2023·12 cites·29 claims
- 2898US11613536B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2021·Granted Mar 28, 2023·15 cites·15 claims
- 2998US11608337B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2020·Granted Mar 21, 2023·15 cites·22 claims
- 3098US11572366B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2020·Granted Feb 7, 2023·15 cites·28 claims
- 3198US11530214B2Bicyclic heterocycles as FGFR inhibitorsINCYTE CORP·Filed 2021·Granted Dec 20, 2022·7 cites·26 claims
- 3298US11465981B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2020·Granted Oct 11, 2022·18 cites·28 claims
- 3398US11414433B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2020·Granted Aug 16, 2022·23 cites·50 claims
- 3498US11407749B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2020·Granted Aug 9, 2022·23 cites·24 claims
- 3598US11401279B2Pyrido[3,2-d]pyrimidine compounds as immunomodulatorsINCYTE CORP·Filed 2020·Granted Aug 2, 2022·24 cites·14 claims
- 3698US11339149B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2020·Granted May 24, 2022·24 cites·20 claims
- 3798US11173162B2Bicyclic heterocycles as FGFR4 inhibitorsINCYTE CORP·Filed 2020·Granted Nov 16, 2021·22 cites·19 claims
- 3898US11124511B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2020·Granted Sep 21, 2021·28 cites·35 claims
- 3998US11104682B2Salts of TAM inhibitorsINCYTE CORP·Filed 2020·Granted Aug 31, 2021·7 cites·35 claims
- 4098US11066394B2Solid forms of an HPK1 inhibitorINCYTE CORP·Filed 2020·Granted Jul 20, 2021·12 cites·44 claims
- 4198US11053246B2Substituted tricyclic compounds as FGFR inhibitorsINCYTE CORP·Filed 2020·Granted Jul 6, 2021·23 cites·10 claims
- 4298US11014923B2Bicyclic heterocycles as FGFR4 inhibitorsINCYTE CORP·Filed 2020·Granted May 25, 2021·22 cites·32 claims
- 4398US10947230B2Bicyclic heterocycles as FGFR inhibitorsINCYTE CORP·Filed 2019·Granted Mar 16, 2021·26 cites·44 claims
- 4498US10906920B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2020·Granted Feb 2, 2021·29 cites·41 claims
- 4598US10813930B2Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3INCYTE CORP·Filed 2019·Granted Oct 27, 2020·27 cites·42 claims
- 4698US10800768B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2019·Granted Oct 13, 2020·30 cites·18 claims
- 4798US10793565B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2019·Granted Oct 6, 2020·27 cites·16 claims
- 4898US10738048B2Bicyclic heterocycles as FGFR4 inhibitorsINCYTE CORP·Filed 2019·Granted Aug 11, 2020·28 cites·21 claims
- 4998US10669271B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2019·Granted Jun 2, 2020·40 cites·20 claims
- 5098US10632126B2Bicyclic heterocycles as FGFR4 inhibitorsINCYTE CORP·Filed 2019·Granted Apr 28, 2020·27 cites·8 claims
Showing the top 50 of 956 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when INCYTE CORP files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →